DISP2 inhibitors encompass a category of chemical compounds designed to selectively obstruct the functional activities of the Dispatched Homolog 2 (DISP2) protein. DISP2, a member of the Dispatched family, plays a critical role in the secretion and movement of the signaling molecule Hedgehog (Hh). The Hh signaling pathway is pivotal in embryonic development and also in the regulation of adult stem cells. Inhibitors targeting DISP2 are specifically crafted to interfere with the release of Hh, thereby attenuating the Hh pathway signaling. The mechanism by which these inhibitors work involves the binding to DISP2, which in turn prevents the proper dispatching of Hh ligands from the producing cells. This blockade is consequential; without the proper distribution of Hh ligands, the subsequent reception by the Patched receptor on neighboring cells is hindered, leading to a downregulation of the pathway's downstream signaling events. The inhibition of this pathway is a point of interest due to the role of aberrant Hh signaling in the pathology of various congenital disorders and its implication in the sustenance of certain cancer cell types.
The specificity of DISP2 inhibitors means that their action is distinct from that of general Hedgehog pathway inhibitors which may target multiple proteins within the pathway. By focusing on DISP2, these inhibitors present a nuanced approach, potentially offering a more targeted means to dampen the Hh pathway without the broad-spectrum effects of pan-Hh inhibitors. The chemical structure of DISP2 inhibitors is designed to ensure high-affinity binding to the DISP2 protein, which is essential for their inhibitory function. This targeted blockade does not influence the initial formation or processing of the Hh precursor, nor does it affect the intracellular signaling mechanisms directly downstream of the Patched receptor. Instead, the inhibitors' role is to stymie the extracellular movement of Hh, which is a crucial step for the paracrine signaling that dictates cellular responses in adjacent tissues. The precise molecular interactions between DISP2 inhibitors and the DISP2 protein remain an area of intensive research, with the aim of elucidating the detailed inhibitory mechanisms that govern the modulation of Hh signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Inhibits the Hedgehog (Hh) signaling pathway by directly targeting Smoothened (SMO), which is required for the activation of the pathway and subsequent DISP2 function, leading to reduced DISP2-mediated release of Hh ligands. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $82.00 $158.00 | 1 | |
Specifically binds to and inhibits SMO, a component of the Hh signaling pathway. DISP2 is implicated in the release of Hh ligands, and inhibition of SMO by Vismodegib reduces the functional activity of DISP2. | ||||||
GANT61 | 500579-04-4 | sc-202630 sc-202630A sc-202630B | 1 mg 5 mg 10 mg | $64.00 $131.00 $204.00 | 6 | |
Acts as a GLI antagonist, blocking the final step in the Hh pathway. Since DISP2 is involved in the upstream release of Hh ligands, inhibiting downstream GLI function can indirectly decrease DISP2 activity. | ||||||
Jervine | 469-59-0 | sc-200934 sc-200934A | 1 mg 5 mg | $66.00 $240.00 | 1 | |
Alkaloid that interferes with the Hh signaling pathway similar to Cyclopamine. It binds to SMO, inhibiting the pathway and indirectly reducing DISP2 activity by preventing the proper processing and release of Hh proteins. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
While primarily an antifungal agent, it also inhibits SMO and therefore the Hh pathway. This reduces DISP2 activity by lowering the demand for its function in Hh ligand release. | ||||||
Erismodegib | 956697-53-3 | sc-396280 sc-396280A | 10 mg 100 mg | $255.00 $918.00 | ||
Inhibits SMO, affecting the Hh signal transduction and indirectly leading to a decrease in DISP2 activity, as DISP2-mediated Hh ligand release is not required when the pathway is blocked. | ||||||
Glasdegib | 1095173-27-5 | sc-507353 | 5 mg | $165.00 | ||
Works as an antagonist to SMO, halting the Hh pathway. This action indirectly inhibits DISP2 by decreasing the need for its Hh ligand release function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor, indirectly affects the Hh pathway and possibly DISP2 function due to the complex interplay of PI3K signaling with other pathways that may converge on Hh signaling. | ||||||